Target validation and analysis in normal and diseased human brain tissue

Diereks2_wide.jpg

Diereks4wide.jpg

graphic_w.jpg

Jennifer SVZ amyg wide.jpg

Shelfw.jpg

THE NEUROVALIDA PLATFORM:

Assists companies and academia by providing services for CNS drug target validation, discovery and testing utilising adult human brain tissue microarrays, automated microscopy, automated (high content) image analysis and adult human brain cell culture.

WE PROVIDE TWO LEVELS OF SERVICES:

  • Target validation and analysis where the client is sent high resolution digitised images of their target in human brain and a detailed report of our analysis.
  • Partnering with Biotech/Pharma/Academia to deliver a collaborative programme of research around target discovery and testing using a range of techniques on human brain tissues and cells.

The principal goal for Neurovalida is to engage in contracts and collaborations with commercial entities to promote the development of medications for treating human brain disorders. Neurovalida will design and undertake research programmes utilising human brain tissue and/or cells for clients to achieve this goal at the highest ethical and scientific standards. Most importantly, this work recognises the wishes of the generous human brain and brain tissue donors and their families to help develop treatments for these devastating brain disorders. 

NEUROVALIDA DEVELOPED BY:

Professor Mike Dragunow, Professor Richard Faull and Associate Professor Maurice Curtis with a vision to promote the translation of CNS drug discovery to the clinic by improving drug target validation utilising their expertise in human brain banking, tissue microarray and high content screening.